The Outcome of Subthalamic Deep Brain Stimulation in Advanced Parkinson's Disease and Morphometry

NCT06095245 | Active Not Recruiting

• 1 other identifier: 7435
• Study Type: observational
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

The research will evaluate possible clinical and individual brain topographic features affecting the outcome in subthalamic deep brain stimulation (DBS) with patients with Parkinson's disease (PD). The patient cohort consists 35 PD patients treated with subthalamic DBS in 2020-2022. The clinical features (such as age, disease duration, response to levodopa in the levodopa challenge test) will be evaluated retrospectively from the medical records and brain topographic features from the preoperative 3 Tesla brain imaging.

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• The clinical outcome of subthalamic DBS as evaluated with UPDRS III and levodopa equivalent daily dosage changes

  The UPDRS III scores and levodopa equivalent daily dosage at baseline and at 6-month's visit will be evaluated and the changes will be analyzed as clinical outcome of DBS treatment

  6 months

Secondary Outcomes (1)

• The patients' individual brain tomographic features affecting the DBS outcome

  6 months

Study Arms (1)

35 patients with advanced PD treated with subthalamic deep brain stimulation

35 patients with advanced PD treated with subthalamic deep brain stimulation. The decision of DBS treatment had been performed on the clinical decision by the treating neurologist and the patients. Patients are between 18 and 80 years old.

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consists of patients with Parkinson's disease and treated with subthalamic DBS in HUS

You may qualify if:

• Advanced Parkinson's disease and subthalamic deep brain stimulation treatment. The DBS screening and operation done in Helsinki University Hospital (HUS)

You may not qualify if:

• Patients with Parkinson's disease and not treated with subthalamic DBS in HUS

Sponsors & Collaborators

• Hospital District of Helsinki and Uusimaa: lead

Study Sites (1)

Department of Neurology and department of Neurosurgery Helsinki University Hospital

Helsinki, 00029 HUS, Finland

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: M.D., Specialist in Neurology

Study Record Dates

• First Submitted: September 26, 2023
• First Posted: October 23, 2023
• Study Start: December 1, 2022
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: March 29, 2024

Record last verified: 2024-03

Locations

FI (1)